Irinotecan-cisplatin interactions assessed in cell-based screening assays: Cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 91-102

  Zastre, Jason ^a   Anantha, Malathi ^b   Ramsay, Euan ^b   Bally, Marcel ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cisplatin; Irinotecan; Non small cell lung carcinoma; Synergistic drug combination

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CISPLATIN; IRINOTECAN; LACTONE; PLATINUM;

ARTICLE; CANCER CELL CULTURE; CELL PH; CONTROLLED STUDY; DNA ADDUCT; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG SCREENING; DRUG UPTAKE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METHODOLOGY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; LACTONES; LUNG NEOPLASMS; TIME FACTORS;

EID: 34247324700     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0353-z     Document Type: Article

References (41)

1. Adams DJ, Wahl ML, Flowers JL, Sen B, Colvin M, Dewhirst MW, Manikumar G, Wani MC (2006) Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol 57:145-154
2. Akimoto K, Kawai A, Ohya K (1994) Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull 42:2135-2138
3. Atsumi R, Okazaki O, Hakusui H (1995) Metabolism of Irinotecan to SN-38 in a tissue-isolated tumor model. Biol Pharm Bull 18:1024-1026
4. Boyd G, Smyth JF, Jodrell DI, Cummings J (2001) High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells. Anal Biochem 297:15-24
5. Burke TG, Munshi CB, Mi Z, Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84:518-519
6. Chauvier D, Chourpa I, Maizieres M, Riou J-F, Dauchez M, Alix AJP, Manfait M (2003) E-ring conformation has a key role in cleavable complex formation: homocamptothecin versus camptothecins. J Mol Struct 651-653:55-65
7. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
8. Gabr A, Kuin A, Aalders M, El-Gawly H, Smets LA (1997) Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 57:4811-4816
9. Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56:1194-1198
10. Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS (2000) Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann N Y Acad Sci 922:27-35
11. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422
12. Goldwasser F , Valenti M, Torres R, Kohn KW, Pommier Y (1996) Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 2:687-693
13. Guemei AA, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov MV, Grem JL, Ismail AS, Bowen D, Taylor RE, Takimoto CH (2001) Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother Pharmacol 47:283-290
14. Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179-187
15. Kakolyris S, Kouroussis C, Souglakos J, Agelaki S, Kalbakis K, Vardakis N, Vamvakas L, Georgoulias V (2001) Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S71-S76
16. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610
17. Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K (2001) In vitro synergistic interactions between the cisplatin analog nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7:202-209
18. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191
19. Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H (1999) pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491-496
20. Kohn KW, Pommier Y (2000) Molecular and biological determinants of the cytotoxic actions of camptothecins: perspective for the development of new topoisomerase I inhibitors. Ann N Y Acad Sci 922:11-26
21. Komuro Y, Udagawa Y, Susumu N, Aoki D, Kubota T, Nozawa S (2001) Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the inffux and effux system of cisplatin. Jpn J Cancer Res 92:1242-1250
22. Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM , Pommier Y (2002) Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41:1428-1435
23. Laurencot CM, Kennedy KA (1995) Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells. Oncol Res 7:371-379
24. Liu LF, Desai SD, Li T-K, Mao Y, Sun M, Sim S-P (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1-10
25. Ma JG, Maliepaard M, Nooter K, Boersma AWM, Verweij J, Stoter G, Schellens JHM (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of 8 solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307-316
26. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780
27. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y (1995) Inhibition of removal of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-links by 7-ethyl-10-hydroxycamptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75
28. Mathijssen RHJ, Loos WJ, Verweij J, Sparreboom A (2002) Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103-123
29. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5:1854-1863
30. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N (1994) Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85:966-971
31. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H , Fukuoka M (2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335-341
32. Ohtsuka Kimihiko, Inoue Shoichi, Kameyama Masayo, Kanetoshi Akio, Fujimoto Toru, Takaoka Kazuo, Araya Yoshikazu, Shida Akira (2003) Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 41:187-198
33. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J (2002) Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 49:329-335
34. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB (2005) The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2:341-351
35. Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, Cummings OW, Seitz DE, Bosron WF (2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9:4983-4991
36. Tsunoda T, Tanimura H, Hotta T, Tani M, Iwahashi M, Ishimoto K, Tanaka H, Matsuda K, Yamaue H (2000) In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. J Surg Oncol 73:6-11
37. Van Ark-Otte J, Kedde MA, Van Der Vijgh WJF, Dingemans AMC, Jansen WJM, Pinedo HM, Boven E, Giaccone G (1998) Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 77:2171-2176
38. van Waardenburg RCAM, de Jong LA, van Eijndhoven MAJ, Verseyden C, Pluim D, Jansen LET, Bjornsti M-A, Schellens JHM (2004) Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem 279:54502-54509
39. Vukovic V, Tannock IF (1997) Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 75:1167-1172
40. Xu G, Zhang W, Ma MK, McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611
41. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F (1999) Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189-1196